Comparative Pharmacology
Head-to-head clinical analysis: AKTIPAK versus CILOXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKTIPAK versus CILOXAN.
AKTIPAK vs CILOXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alvimopan is a selective, peripherally acting mu-opioid receptor antagonist. It blocks opioid binding at gastrointestinal mu-opioid receptors, thereby reversing opioid-induced bowel dysfunction without affecting central analgesia.
Ciprofloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and transcription.
See full prescribing information. AKTIPAK is not a recognized drug. Assuming a hypothetical drug, typical adult dosing is unavailable.
1-2 drops in affected eye(s) every 2 hours while awake for 2 days, then every 4 hours for 5 days; or 1-2 drops 4 times daily for 7 days. Ointment: ½-inch ribbon into conjunctival sac 3 times daily for 2 days, then 2 times daily for 5 days.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life approximately 4 hours in patients with normal renal function; extended to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 24 hours in severe impairment (CrCl <30 mL/min)
Primarily renal excretion as unchanged drug (approx. 70%) and metabolites (30%). Biliary/fecal excretion accounts for less than 5%.
Renal: 50-70% unchanged drug; biliary: 15-20% as metabolites; fecal: 20-35%
Category C
Category C
Fluoroquinolone Antibiotic (Ophthalmic)
Fluoroquinolone Antibiotic (Ophthalmic)